Novo Nordisk Post Strong Q2 Results

Novo Nordisk has announced another strong set of results, aided by strong sales of their diabetes drug, Victoza. The company’s net profit for the second quarter increased by 26% to 6.73 billion Danish kroner (equal to roughly $1.20 billion), while sales grew 10% to 21.38 billion kroner. The organisation’s group of modern insulin products, including

Continue Reading

Novo Nordisk Q3 Net Profit Grows 26%

Novo Nordisk revealed more healthy sales figures yesterday for their third quarter results, aided by solid sales of their diabetes drug, Victoza, and its modern insulins. The company announced an 18% growth in sales to a total of 57.1 billion Danish kroner ($9.9 billion).  Operating profit increased 34% to 21.9 billion kroner.  Their net profit

Continue Reading

Novo Nordisk Q3 Net Profit Grows 26%

Novo Nordisk revealed more healthy sales figures yesterday for their third quarter results, aided by solid sales of their diabetes drug, Victoza, and its modern insulins. The company announced an 18% growth in sales to a total of 57.1 billion Danish kroner ($9.9 billion).  Operating profit increased 34% to 21.9 billion kroner.  Their net profit

Continue Reading